Vista Pharmaceuticals (524711) Q2 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and half year ended September 30, 2024, and reviewed the limited review report from auditors.

• Financial results were prepared in accordance with Indian Accounting Standards (Ind AS) and reviewed by statutory auditors.

Financial highlights

• Total revenue for Q2 FY25 was ₹250.17 lakhs, down from ₹354.94 lakhs in Q2 FY24.

• Loss before tax for Q2 FY25 was ₹125.20 lakhs, an improvement from a loss of ₹158.88 lakhs in Q2 FY24.

• Net loss for Q2 FY25 stood at ₹97.37 lakhs, compared to ₹85.70 lakhs in Q1 FY25 and ₹201.93 lakhs in Q2 FY24.

• Total comprehensive loss for the half year ended September 2024 was ₹182.66 lakhs.

• Basic EPS for Q2 FY25 was (₹0.16), compared to (₹0.46) in Q2 FY24.

Outlook and guidance

• Results for the quarter are available on the BSE, NSE, and company websites.